Dinh, Timothy A.
Utria, Alan F. http://orcid.org/0000-0003-2431-7611
Barry, Kevin C.
Ma, Rosanna
Abou-Alfa, Ghassan K.
Gordan, John D.
Jaffee, Elizabeth M. http://orcid.org/0000-0003-3841-6549
Scott, John D.
Zucman-Rossi, Jessica http://orcid.org/0000-0002-5687-0334
O’Neill, Allison F.
Furth, Mark E.
Sethupathy, Praveen
Article History
Accepted: 13 January 2022
First Online: 21 February 2022
Competing interests
: E.M.J. is a paid consultant for the following companies: Adaptive Biotech, Cstone Pharmaceuticals, Achilles Therapeutics, DragonFly Therapeutics, Candel Therapeutics and Genocea Biosciences. She receives funding from Lustgarten Foundation and Bristol Myers Squibb. She is the Chief Medical Advisor for Lustgarten and SAB advisor to the Parker Institute for Cancer Immunotherapy (PICI) and for the C3 Cancer Institute. She is a founding member of Abmeta. G.K.A.-A. has had research support from Arcus, Agios, AstraZeneca, Bayer, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Sillajen, and Yiviva. He has also provided consulting to Agios, AstraZeneca, Alnylam, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Loxo, Merck, MINA, QED, Redhill, Rafael, Silenseed, Sillajen, Sobi, Surface Oncology, Therabionics, Twoxar, Vector and Yiviva. M.E.F. is employed full-time by the Fibrolamellar Cancer Foundation, a registered non-profit corporation (501c3) in the USA. The following authors serve on the advisory board of the Fibrolamellar Cancer Foundation: E.M.J., J.D.S., J.D.G., G.K.A.-A., A.F.O'N. and J.Z.-R. The following authors are past or current recipients of grant funding from the Fibrolamellar Cancer Foundation: J.D.S., J.D.G., G.K.A.-A., K.C.B. and P.S. T.A.D., A.F.U. and R.M. declare no competing interests.